Home Healthcare Pharmaceuticals Sickle Cell Disease Treatment Market

Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Blood Transfusion, Stem Cell Transplant, Pharmacotherapy, Hydroxyurea, L-Glutamine, Crizanlizumab, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Academic & Research Institute) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 17, 2026 | Author: Dhanashri B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Sickle Cell Disease Treatment Market, By Treatment Type 2022-2034 (USD MILLION/ Units)
    1. Blood Transfusion
    2. Stem Cell Transplant
    3. Pharmacotherapy
    4. Hydroxyurea
    5. L-Glutamine
    6. Crizanlizumab
    7. Others
      1. Gene Therapy
  2. Sickle Cell Disease Treatment Market, By End User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Specialty Clinics
    3. Ambulatory Surgical Centers
    4. Academic & Research Institute
  3. Regional Sickle Cell Disease Treatment Market
    1. North America
      1. North America Sickle Cell Disease Treatment Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
      2. North America Sickle Cell Disease Treatment Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Academic & Research Institute
      3. U.S.
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      4. Canada
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
    2. Europe
      1. Europe Sickle Cell Disease Treatment Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
      2. Europe Sickle Cell Disease Treatment Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Academic & Research Institute
      3. U.K.
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      4. Germany
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      5. France
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      6. Spain
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      7. Italy
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      8. Russia
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      9. Nordic
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      10. Benelux
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      11. Rest of Europe
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
    3. APAC
      1. APAC Sickle Cell Disease Treatment Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
      2. APAC Sickle Cell Disease Treatment Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Academic & Research Institute
      3. China
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      4. Korea
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      5. Japan
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      6. India
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      7. Australia
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      8. Taiwan
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      9. South East Asia
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      10. Rest of Asia-Pacific
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
    4. Middle East and Africa
      1. Middle East and Africa Sickle Cell Disease Treatment Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
      2. Middle East and Africa Sickle Cell Disease Treatment Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Academic & Research Institute
      3. UAE
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      4. Turkey
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      5. Saudi Arabia
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      6. South Africa
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      7. Egypt
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      8. Nigeria
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      9. Rest of MEA
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
    5. LATAM
      1. LATAM Sickle Cell Disease Treatment Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
      2. LATAM Sickle Cell Disease Treatment Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Academic & Research Institute
      3. Brazil
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      4. Mexico
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      5. Argentina
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      6. Chile
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      7. Colombia
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
      8. Rest of LATAM
        1. Blood Transfusion
        2. Stem Cell Transplant
        3. Pharmacotherapy
        4. Hydroxyurea
        5. L-Glutamine
        6. Crizanlizumab
        7. Others
          1. Gene Therapy
        8. Hospitals
        9. Specialty Clinics
        10. Ambulatory Surgical Centers
        11. Academic & Research Institute
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.